HUE030005T2 - Biomarkerek a rákbetegség elleni immunterápia hatékonyságának elõrejelzésére - Google Patents
Biomarkerek a rákbetegség elleni immunterápia hatékonyságának elõrejelzésére Download PDFInfo
- Publication number
- HUE030005T2 HUE030005T2 HUE11788121A HUE11788121A HUE030005T2 HU E030005 T2 HUE030005 T2 HU E030005T2 HU E11788121 A HUE11788121 A HU E11788121A HU E11788121 A HUE11788121 A HU E11788121A HU E030005 T2 HUE030005 T2 HU E030005T2
- Authority
- HU
- Hungary
- Prior art keywords
- cancer
- patients
- patient
- group
- tumor
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
- G01N2333/521—Chemokines
- G01N2333/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1or LDCF-2
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/775—Apolipopeptides
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Analytical Chemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Tropical Medicine & Parasitology (AREA)
- Toxicology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Claims (7)
- BIOM ΛΒMEREK A RÁKBETEGSÉG ELLEN 1 ΙΜΜΗΧΪΕΚΑΙΜΑ HATÉKONYSÁGÁNAK ELŐREJELZÉSÉRE Sz 8 b ad a S t n i t gén vpon tök1, Az immintteráftia által a rákbetegre ki fejseit jótékony hatás előrejelzésére szolgáló in vitro módszer, amely az említett rákbstégtöl véti. minta apolípoptotein Aí (AjxjAH szintjének meghatározáséi foglalja magában, - ahol a ráfcbetegek adott populációjának médián markerssintjéi legalább 10%-kal meghaladó markersSint jelzi az immnoterápia állal az etnlitett tákbetegre kifejteit jótékony itatást, - ahol az említett rákbetég a vesesejtes k&rcinómái (RCC), kolorektális rákot (CRC), gyomorrákot (GC), me-lanömát, nem kissejtes íüdötaköt (NSCCC), gUóbiasztótöát és bármilyen típusú ádénökardnómál. magában. foglaló csoportból választott rákbetegségben szenved; - ahol áz említett minta a teljes vért, perifériás vert vagy annak frakcióit, szérumot·, határréteget, dagaítaiszövetet. nyirokfbíyadékot, vizeletét, csöBtveiéh EDTA-s plazmát, h.eparlnös plazmát, cttfáíss plazmát, heparinos teljes vért és ezek fagyasztott mintáit, á fagyasztott hepafinös teljés Vért is idsértvg, magába·) foglaló csoportból választott minta; - ahol az -említeti meghatározás- az inmuateszteket, gyöngy alapú immunteszteket, kombinált imnimitesZíékét, ELíSáb, micröárráy alapó. teszteket, cpigenetikai teszteket, expresszié elemzést, FACS elemzést, bizonyított hematológiai módszereket és tömegspsktmunemát -magában foglaló csoportból választott legalább egy módszer; - ahol az említett immonte.rápk: rákellenes védőoltással végzett vaketnálásből áll, ahol az említett vakekíáüs a SHQ 1D NO: ! -VE szekvencia szerinti; peptkiekből átlő csoportból választott legalább egy immunogen pepiidéi tartalmazó legalább egy védőoltás; és - ahol az említett jótékony hatás a hosszabb teljes túlélést, az -ímtöuttterápia Útján indúkáh: egyszeres és/vagy többszörös T-sejt választ, a daganat növekedésének gátlását, a daganat zsugorítását: és a hosszabb progressziómentes felélést magában foglaló csoponból választható.
- 2, Az í . igénypont szerinti módszer, amely továbbá a B-sejieket vonzó kemokiat (CXCLi3-;BCA-}), nentrofflekeí, interleakim-6-ot: '(11,-6) ős rövid láncő aeilkarnithieket magában foglaló csoportból választott legalább egy mafkemek az említett rákbetegtöl .származó mintában, lévő szintjének méréséből, áll,, ahol a rákbetegek adott populációjának médián marfcerszintjénéi legalább ,i0%-kai alacsonyabb markersziöí jelzi, az temmöterápia által az említett rákbetegre kifej tett jótékony hatást, 3, A-z 3. vagy 2. Igénypont szerint módszer, ahol az .említett, védőoltás -segédanyagot, például GM-CSP-ei tartalmaz.
- 4. Az 1-3, igénypont sz.srinti módszer, amely továbbá az említett betegtől veit említeti mintában lévő zlímmínt és áirekt bd bubit» magában feglaló csoportból választott legalább egy maikét szintjének rttegh&tátozásáfeóí. álló lépést tattobnazza, ahol & r&kbeiegek adott populációjámík: médián markerszmíjét legalább H)%-kai meghaladó m&tkemziot jelzi az ihnnnmerapia által az említett rákbetegre kifejtett jótékony Itatást, és opcionálisa» a»· említett betegtől vett említett mintában lóvd mterleokm-B- (11,-33) marker szintjének meghatározását tartalmazza, ahol á rákbetegek adott populációjának médián markerszintjénél legalább 10%-kal alacsonyabb rnárkerszim jelzi az imrínudetápla által az említett rák be tegre kife j tett jótékony hatást,
- 5. Az 1-4. igénypont szerinti módszer, amelynek sétán az' említett beteget a sebészeti irtíitétböl, sugárterápiából és/Vagv kemoterápiából álló terápiákkal kezelik vagy előkezeltek,.például m említett betegnek a eitokinek, a íírozinklnáz inhibitorok OKI), mini a szomfenib és a szunitinib, és a ciklolbszfíimid köziií választott rákellenes anyaggal végzet; kezeléséből vagy előkezeléséből álló terápiák, $< .Az 1--5. igénypont szerinti módszer, amely továbbá az említett módszerre alapozva prognosztizálja az említett.betegnél végzek említett unmunterápia hatását.
- 7, .Az i-ő. igény-pont szerinti módszer, amely továbbá az -említett módszerre alapozva monitorozza az említett betegnél végzett említett rákkezelés hatását, ahol a monitorozás az említeti snegltetározási lépés legalább egy alkalommal történő megismétléséből áll. 8v. Az í··? igénypont szeriéit módszer, amelyben az említett legalább egy iíamunogén pepiidet a S.EQ 11D NO: 1- H), csoportból választják.
- 9, Az 1-7, igénypont szerinti módszer, amelyben az: említett legalább egy immunogen pepiidet á SEQ lt> NO: I, 5, 8, 9 és 11-3§. csoportból választják,
- 18, As 1-7. igénypont szerinti módszer, amelyben az említett legalább egy ínnmmogéu pepiidet a SEQ XD NO: 20-29, csoportból választják, IL Az 1-7. igénypont szérimi módszer, amelyben az említett legalább egv tnununogési pepiidet a SEQ 1D NO: 30-37. csoportból választják.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US41698110P | 2010-11-24 | 2010-11-24 | |
GBGB1021289.2A GB201021289D0 (en) | 2010-12-15 | 2010-12-15 | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
US42365210P | 2010-12-16 | 2010-12-16 |
Publications (1)
Publication Number | Publication Date |
---|---|
HUE030005T2 true HUE030005T2 (hu) | 2017-04-28 |
Family
ID=43567254
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HUE11788121A HUE030005T2 (hu) | 2010-11-24 | 2011-11-22 | Biomarkerek a rákbetegség elleni immunterápia hatékonyságának elõrejelzésére |
Country Status (17)
Country | Link |
---|---|
US (2) | US8669063B2 (hu) |
EP (1) | EP2643698B1 (hu) |
JP (1) | JP6005051B2 (hu) |
KR (1) | KR20130119453A (hu) |
CN (1) | CN103384827B (hu) |
AU (1) | AU2011333819A1 (hu) |
BR (1) | BR112013012820A2 (hu) |
CA (1) | CA2818738A1 (hu) |
EA (1) | EA201390762A1 (hu) |
ES (1) | ES2592957T3 (hu) |
GB (1) | GB201021289D0 (hu) |
HU (1) | HUE030005T2 (hu) |
MX (1) | MX341734B (hu) |
NZ (1) | NZ609712A (hu) |
PL (1) | PL2643698T3 (hu) |
SG (1) | SG190698A1 (hu) |
WO (1) | WO2012069462A1 (hu) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2172211B1 (en) | 2008-10-01 | 2014-12-03 | Immatics Biotechnologies GmbH | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of glioblastoma (GBM) and other cancers |
GB201004551D0 (en) | 2010-03-19 | 2010-05-05 | Immatics Biotechnologies Gmbh | NOvel immunotherapy against several tumors including gastrointestinal and gastric cancer |
US9026531B2 (en) * | 2012-04-17 | 2015-05-05 | Cerner Innovation, Inc. | Associating multiple data sources into a web-accessible framework |
JP6355630B2 (ja) | 2012-06-26 | 2018-07-11 | バイオデシックス・インコーポレイテッドBiodesix Inc | 質量スペクトルを用いて免疫応答発生治療剤で治療する癌患者を選択または除外する方法 |
CN103048453B (zh) * | 2012-12-18 | 2014-11-26 | 苏州浩欧博生物医药有限公司 | 一种糖类抗原ca19-9的纳米磁微粒化学发光测定试剂盒及其制备方法和检测方法 |
CN105814571B (zh) * | 2013-11-07 | 2020-01-07 | 曼迪奥研究有限公司 | 肺癌评估系统及计算机可读介质 |
EP2942629A1 (en) * | 2014-05-08 | 2015-11-11 | Universität Würzburg | Predictive markers for successful cancer immunotherapy |
GB201505585D0 (en) * | 2015-03-31 | 2015-05-13 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds for use in immunotherapy against renal cell carinoma (RCC) and other cancers |
US20180371550A1 (en) * | 2015-07-08 | 2018-12-27 | Children's Hospital Medical Center | Loss of transcriptional fidelity leads to immunotherapy resistance in cancers |
CN108027373B (zh) * | 2015-07-13 | 2021-04-09 | 佰欧迪塞克斯公司 | 受益于阻断t细胞程序性细胞死亡1(pd-1)检查点蛋白的配体活化的抗体药物的黑素瘤患者的预测性测试和分类器开发方法 |
RU2729116C2 (ru) | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
WO2017136139A1 (en) | 2016-02-01 | 2017-08-10 | Biodesix, Inc. | Predictive test for melanoma patient benefit from interleukin-2 (il2) therapy |
CN105624110A (zh) * | 2016-02-29 | 2016-06-01 | 时宏珍 | Hla-a0201限制性抗psa抗原特异性ctl的制备方法 |
US20190309369A1 (en) * | 2016-05-09 | 2019-10-10 | Inserm (Institute National De La Sante Et De La Recherche Medicale) | Methods for classifying patients with a solid cancer |
WO2018039452A1 (en) * | 2016-08-24 | 2018-03-01 | The Wistar Institute Of Anatomy And Biology | Methods of treating cancers with chemotherapy with reduced toxicity |
CN106198987A (zh) * | 2016-08-31 | 2016-12-07 | 辽宁迈迪生物科技股份有限公司 | 一种用于评价肿瘤免疫细胞疗法的检测标记物及其检测方法和应用 |
DE102016123893A1 (de) | 2016-12-08 | 2018-06-14 | Immatics Biotechnologies Gmbh | T-Zellrezeptoren mit verbesserter Bindung |
NZ754222A (en) | 2016-12-08 | 2022-02-25 | Immatics Biotechnologies Gmbh | T cell receptors with improved pairing |
WO2018129301A1 (en) * | 2017-01-05 | 2018-07-12 | Biodesix, Inc. | Method for identification of cancer patients with durable benefit from immunotherapy in overall poor prognosis subgroups |
US10699007B2 (en) * | 2017-03-13 | 2020-06-30 | Oracle International Corporation | Hybrid univariate/multivariate prognostic-surveillance technique |
KR102018006B1 (ko) * | 2017-06-02 | 2019-09-04 | 이종균 | 대장 직장암 환자와 정상인의 말초혈액 내 면역세포의 분포 차이를 이용하여 면역력을 평가하고 암 발병 유무에 대한 정보를 제공하는 방법 및 이를 이용한 진단키트 |
KR20200087143A (ko) | 2017-10-10 | 2020-07-20 | 그릿스톤 온콜로지, 인코포레이티드 | 핫스팟을 이용한 신생항원 동정 |
US11885815B2 (en) | 2017-11-22 | 2024-01-30 | Gritstone Bio, Inc. | Reducing junction epitope presentation for neoantigens |
EP3773691A4 (en) | 2018-03-29 | 2022-06-15 | Biodesix, Inc. | DEVICE AND METHOD FOR IDENTIFICATION OF PRIMARY IMMUNORESISTANCE IN CANCER PATIENTS |
WO2019195823A1 (en) * | 2018-04-06 | 2019-10-10 | The Board Of Regents Of The University Of Texas System | Prediction and treatment of immunotherapeutic toxicity |
CN108624650B (zh) * | 2018-05-14 | 2022-04-29 | 乐普(北京)医疗器械股份有限公司 | 判断实体瘤是否适合免疫治疗的方法和检测试剂盒 |
CN110885886B (zh) * | 2018-09-07 | 2023-04-07 | 华中科技大学同济医学院附属协和医院 | 一种胶质母细胞瘤鉴别诊断及胶质瘤生存预后的分型方法 |
KR102159538B1 (ko) * | 2019-01-11 | 2020-09-24 | 충남대학교 산학협력단 | 폐암 환자의 면역항암제에 대한 치료 반응성 예측용 il-6 마커 및 이의 용도 |
WO2020180424A1 (en) | 2019-03-04 | 2020-09-10 | Iocurrents, Inc. | Data compression and communication using machine learning |
US20220165362A1 (en) * | 2019-03-28 | 2022-05-26 | Hoffmann-La Roche Inc. | Cancer prognosis |
CN111257563B (zh) * | 2020-01-22 | 2022-08-23 | 广州泛恩生物科技有限公司 | Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途 |
IL299323A (en) * | 2020-06-21 | 2023-02-01 | Oncohost Ltd | Repository signatures for predicting response to immunotherapy |
WO2022006514A1 (en) * | 2020-07-02 | 2022-01-06 | Gopath Laboratories Llc | Immune profiling and methods of using same to predict responsiveness to an immunotherapy and treat cancer |
CN113219173A (zh) * | 2021-05-11 | 2021-08-06 | 中南大学湘雅医院 | Sh2b1在肺癌诊断中的应用 |
CN113462776B (zh) * | 2021-06-25 | 2023-03-28 | 复旦大学附属肿瘤医院 | m6A修饰相关联合基因组在预测肾透明细胞癌患者免疫治疗疗效中的应用 |
CN115058440B (zh) * | 2022-06-08 | 2023-08-15 | 郑州轻工业大学 | 催化合成天然蔗糖酯的工程菌及其构建方法和应用 |
CN115612737A (zh) * | 2022-08-03 | 2023-01-17 | 皖南医学院第一附属医院(皖南医学院弋矶山医院) | 一种胃癌免疫治疗疗效预测和预后评估的方法及其应用 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AUPM322393A0 (en) | 1993-12-24 | 1994-01-27 | Austin Research Institute, The | Mucin carbohydrate compounds and their use in immunotherapy |
JP3490893B2 (ja) * | 1998-06-02 | 2004-01-26 | 富士レビオ株式会社 | 胃癌の診断方法 |
WO2005098446A2 (en) * | 2004-03-31 | 2005-10-20 | The Johns Hopkins University | Biomarkers for ovarian cancer |
EP1777523A1 (en) | 2005-10-19 | 2007-04-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method |
EP1943521A4 (en) * | 2005-11-02 | 2009-12-30 | Bayer Healthcare Llc | METHOD FOR PREDICTING AND FORECASTING CANCER AND MONITORING CANCER THERAPY |
US20090035801A1 (en) * | 2005-12-27 | 2009-02-05 | Power3 Medical Products, Inc. | Twelve (12) protein biomarkers for diagnosis and early detection of breast cancer |
ES2351623T3 (es) * | 2006-04-24 | 2011-02-08 | Critical Care Diagnostics, Inc. | Predicción de la mortalidad y detección de una enfermedad grave. |
AT504231A1 (de) * | 2006-10-03 | 2008-04-15 | Hans Dr Loibner | Prädiktive parameter |
EP2178557B1 (en) * | 2007-07-27 | 2017-03-01 | Immatics Biotechnologies GmbH | Composition of tumour-associated peptides and related anti-cancer vaccine |
GB0718167D0 (en) * | 2007-09-18 | 2007-10-31 | Cancer Rec Tech Ltd | Cancer marker and therapeutic target |
EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
EP2105740A1 (en) | 2008-03-28 | 2009-09-30 | Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. | Biomarkers for monitoring or predicting the treatment of cancer |
US20110166838A1 (en) | 2008-06-16 | 2011-07-07 | Sividon Diagnostics | Algorithms for outcome prediction in patients with node-positive chemotherapy-treated breast cancer |
WO2010076322A1 (en) | 2008-12-30 | 2010-07-08 | Siemens Healthcare Diagnostics Inc. | Prediction of response to taxane/anthracycline-containing chemotherapy in breast cancer |
US20100240546A1 (en) * | 2009-03-20 | 2010-09-23 | Samuel Chun Lap Lo | Use of biomarkers for the diagnosis and prognosis of lung cancer |
-
2010
- 2010-12-15 GB GBGB1021289.2A patent/GB201021289D0/en not_active Ceased
-
2011
- 2011-11-22 AU AU2011333819A patent/AU2011333819A1/en not_active Abandoned
- 2011-11-22 US US13/302,674 patent/US8669063B2/en active Active
- 2011-11-22 JP JP2013540324A patent/JP6005051B2/ja not_active Expired - Fee Related
- 2011-11-22 WO PCT/EP2011/070661 patent/WO2012069462A1/en active Application Filing
- 2011-11-22 PL PL11788121.9T patent/PL2643698T3/pl unknown
- 2011-11-22 NZ NZ609712A patent/NZ609712A/en not_active IP Right Cessation
- 2011-11-22 SG SG2013035530A patent/SG190698A1/en unknown
- 2011-11-22 CA CA2818738A patent/CA2818738A1/en not_active Abandoned
- 2011-11-22 ES ES11788121.9T patent/ES2592957T3/es active Active
- 2011-11-22 KR KR1020137015847A patent/KR20130119453A/ko not_active Application Discontinuation
- 2011-11-22 BR BR112013012820A patent/BR112013012820A2/pt active Search and Examination
- 2011-11-22 EP EP11788121.9A patent/EP2643698B1/en active Active
- 2011-11-22 MX MX2013005762A patent/MX341734B/es active IP Right Grant
- 2011-11-22 HU HUE11788121A patent/HUE030005T2/hu unknown
- 2011-11-22 CN CN201180056555.2A patent/CN103384827B/zh not_active Expired - Fee Related
- 2011-11-22 EA EA201390762A patent/EA201390762A1/ru unknown
-
2014
- 2014-01-17 US US14/158,054 patent/US9389235B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
GB201021289D0 (en) | 2011-01-26 |
NZ609712A (en) | 2015-05-29 |
SG190698A1 (en) | 2013-07-31 |
US20140234347A1 (en) | 2014-08-21 |
US9389235B2 (en) | 2016-07-12 |
BR112013012820A2 (pt) | 2017-05-09 |
WO2012069462A1 (en) | 2012-05-31 |
MX341734B (es) | 2016-08-31 |
PL2643698T3 (pl) | 2016-12-30 |
JP2014500493A (ja) | 2014-01-09 |
ES2592957T3 (es) | 2016-12-02 |
CN103384827A (zh) | 2013-11-06 |
EP2643698A1 (en) | 2013-10-02 |
KR20130119453A (ko) | 2013-10-31 |
CN103384827B (zh) | 2016-06-08 |
EP2643698B1 (en) | 2016-06-22 |
MX2013005762A (es) | 2013-08-12 |
US8669063B2 (en) | 2014-03-11 |
EA201390762A1 (ru) | 2013-09-30 |
US20120128702A1 (en) | 2012-05-24 |
CA2818738A1 (en) | 2012-05-31 |
JP6005051B2 (ja) | 2016-10-12 |
AU2011333819A1 (en) | 2013-05-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2643698B1 (en) | Biomarkers for predicting the efficacy of an immunotherapy against cancer | |
EP2619585B1 (en) | Use of myeloid cell biomarkers for the diagnosis of cancer | |
US9846162B2 (en) | Immune biomarkers and assays predictive of clinical response to immunotherapy for cancer | |
Yoshiyama et al. | Personalized peptide vaccination in patients with refractory non-small cell lung cancer | |
Komatsu et al. | Gene expression profiles in peripheral blood as a biomarker in cancer patients receiving peptide vaccination | |
EP2051077A2 (en) | Nucleic acid molecules and proteins for the identification, assessment, prevention, and therapy of ovarian cancer | |
KR20180110133A (ko) | 일차 위선암의 체세포 프로모터 랜드스케이프를 나타내는 후성유전학적 프로파일링 | |
WO2013107907A1 (en) | Method for the prognosis of survival time of a patient suffering from a solid cancer | |
Özkan et al. | Diagnostic validity of serum macrophage inhibitor cytokine and tissue polypeptide-specific antigen in pancreatobiliary diseases | |
Arana Echarri et al. | A phenomic perspective on factors influencing breast cancer treatment: Integrating aging and lifestyle in blood and tissue biomarker profiling | |
Tokumaru et al. | Lymphocyte-to-monocyte ratio is a predictive biomarker of response to treatment with nivolumab for gastric cancer | |
Zhu et al. | CD24, COX-2, and p53 in epithelial ovarian cancer and its clinical significance | |
JP2010520453A (ja) | 前立腺癌、又は前立腺癌に対する体液性免疫応答を同定するための方法、及び組成物 | |
Cernera et al. | Immunocytometric analysis of patients with thymic epithelial tumors revealed that COVID-19 vaccine booster strongly enhanced the immune response | |
Jin et al. | Humoral immune responses against tumor‐associated antigen OVA66 originally defined by serological analysis of recombinant cDNA expression libraries and its potentiality in cellular immunity | |
Xu et al. | CD4+ CD25+ regulatory T cells in patients with advanced gastrointestinal cancer treated with chemotherapy | |
Zhang et al. | BPIFB2 is highly expressed in “cold” lung adenocarcinoma and decreases T cell chemotaxis via activation of the STAT3 pathway | |
CN108427003B (zh) | 检测抗白介素2受体亚基a天然抗体的多肽序列、试剂盒和方法 | |
Chen et al. | Clinical study on IL-8, TNF-α, T-cell subgroup in serum of patients with rectal cancer | |
EP4277924A2 (en) | A cxcr3+ cell or cell preparation for use in cancer treatment | |
Pu et al. | Assessment of Treg and Th17 contents in peripheral blood of patients with non-small cell lung cancer and analysis of their correlation with clinicopathologic characteristics | |
Huang et al. | IJC Metabolic & Endocrine | |
Brkic et al. | SYSTEMIC SCLEROSIS PATIENTS WITH THE INTERFERON TYPE I SIGNATURE SHOW FASTER DISEASE DEVELOPMENT AND HIGH BAFF GENE EXPRESSION AND COLLAGEN SYNTHESIS |